Safety of BKM120 Monotherapy in Advanced Solid Tumor Patients
Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
This is a first-in-man, phase I clinical research study with BKM120, a potent and highly
specific oral pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor. The study consists
of a dose escalation part followed by a MTD expansion part.
Once the MTD has been defined, the MTD expansion part will be opened for enrollment.